BACKGROUND Simple hepatic cysts are relatively common in adults, and mostly appear asasymptomatic incidental radiologic findings. Occasionally, a large cyst will causesymptoms. Elevations in the serum biomarkers prote...BACKGROUND Simple hepatic cysts are relatively common in adults, and mostly appear asasymptomatic incidental radiologic findings. Occasionally, a large cyst will causesymptoms. Elevations in the serum biomarkers protein induced by vitamin Kabsence (PIVKA)-II, cancer antigen (CA) 12-5, and CA19-9 are often associatedwith malignant tumors in the liver or bile ducts. This is the first report to describea case of hepatic cyst with elevated levels of PIVKA-II and CA12-5.CASE SUMMARY An 84-year-old Chinese woman was admitted with gradual abdominal distension.Her symptoms started 1 year ago, and she had poor appetite and a weight loss of5 kg within the past 2 wk. She denied any symptoms associated with abdominalpain, fever and chills, nausea and vomiting, etc. The abdomen was enlarged, morein the right upper quadrant, without tenderness. Laboratory examination showedsignificantly increased serum levels of PIVKA-II, CA12-5, and CA19-9. Acomputed tomography scan revealed multiple round cysts in the liver with clearboundaries. The largest cyst was 20.1 cm × 12.2 cm × 19.6 cm in size, located in theright lobe of the liver with mild dilatation of the intrahepatic bile duct, but therewas no contrast enhancement. Percutaneous drainage on the largest hepatic cystand polycinnamol sclerosing agent injection into the cyst cavity were performed.After treatment, the patient’s symptoms relieved and the elevated serum tumormakers reduced to the normal levels dramatically.CONCLUSION The present report identifies an unusual case of a giant hepatic cyst with markedelevation of serum tumor marker levels of PIVKA-II, CA12-5, and CA19-9. Aftertreatment, these three serum markers dramatically decreased to normal levels.The mechanisms for the elevation of these tumor markers may be as follows: (1) Agiant hepatic cyst compresses the liver, causing injury to the hepatocytes, whichmay lead to secretion of a large amount of PIVKA-II;and (2) Some tumorassociatedantigens, such as carcinoembryonic antigen, CA19-9, CA12-5, andCA15-3, are expressed on inflammatory cells.展开更多
目的探讨贝伐珠单抗靶向治疗卵巢癌对肿瘤标志物的影响。方法选取2019年1月—2021年12月福建医科大学附属福州市第一医院收治的80例卵巢癌患者,根据不同治疗药物进行分组,分别纳入单独行化疗的化疗组和行贝伐珠单抗靶向治疗的靶向组,每...目的探讨贝伐珠单抗靶向治疗卵巢癌对肿瘤标志物的影响。方法选取2019年1月—2021年12月福建医科大学附属福州市第一医院收治的80例卵巢癌患者,根据不同治疗药物进行分组,分别纳入单独行化疗的化疗组和行贝伐珠单抗靶向治疗的靶向组,每组40例。测评2组治疗前后肿瘤标志物蛋白芯片中糖链抗原125(glycoantigens in protein chips-125,CA-125)、人附睾蛋白4(Human epididymal protein 4,HE4)水平及血管内皮生长因子(vascular endothelial growth factor,VEGF)水平,治疗后客观缓解率、疾病控制率、免疫指标、癌症患者生命质量测定量表(quality of life scale for cancer patients,FACT-G)和抑郁自评量表(self-rating depression scale,SDS)、焦虑自评量表(self-rating anxiety scale,SAS)评分。结果治疗后,靶向组治疗客观缓解率为65.00%,疾病控制率为87.50%,高于化疗组的42.50%、70.00%(P<0.05);靶向组CA-125、HE4、VEGF指标低于化疗组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于化疗组,FACT-G评分高于化疗组,而SDS、SAS评分低于化疗组,差异有统计学意义(P<0.05)。结论贝伐珠单抗靶向治疗卵巢癌患者可抑制肿瘤新生血管形成和生长,增强治疗效果,改善患者的心理情绪和生活质量。展开更多
文摘BACKGROUND Simple hepatic cysts are relatively common in adults, and mostly appear asasymptomatic incidental radiologic findings. Occasionally, a large cyst will causesymptoms. Elevations in the serum biomarkers protein induced by vitamin Kabsence (PIVKA)-II, cancer antigen (CA) 12-5, and CA19-9 are often associatedwith malignant tumors in the liver or bile ducts. This is the first report to describea case of hepatic cyst with elevated levels of PIVKA-II and CA12-5.CASE SUMMARY An 84-year-old Chinese woman was admitted with gradual abdominal distension.Her symptoms started 1 year ago, and she had poor appetite and a weight loss of5 kg within the past 2 wk. She denied any symptoms associated with abdominalpain, fever and chills, nausea and vomiting, etc. The abdomen was enlarged, morein the right upper quadrant, without tenderness. Laboratory examination showedsignificantly increased serum levels of PIVKA-II, CA12-5, and CA19-9. Acomputed tomography scan revealed multiple round cysts in the liver with clearboundaries. The largest cyst was 20.1 cm × 12.2 cm × 19.6 cm in size, located in theright lobe of the liver with mild dilatation of the intrahepatic bile duct, but therewas no contrast enhancement. Percutaneous drainage on the largest hepatic cystand polycinnamol sclerosing agent injection into the cyst cavity were performed.After treatment, the patient’s symptoms relieved and the elevated serum tumormakers reduced to the normal levels dramatically.CONCLUSION The present report identifies an unusual case of a giant hepatic cyst with markedelevation of serum tumor marker levels of PIVKA-II, CA12-5, and CA19-9. Aftertreatment, these three serum markers dramatically decreased to normal levels.The mechanisms for the elevation of these tumor markers may be as follows: (1) Agiant hepatic cyst compresses the liver, causing injury to the hepatocytes, whichmay lead to secretion of a large amount of PIVKA-II;and (2) Some tumorassociatedantigens, such as carcinoembryonic antigen, CA19-9, CA12-5, andCA15-3, are expressed on inflammatory cells.
文摘目的探讨贝伐珠单抗靶向治疗卵巢癌对肿瘤标志物的影响。方法选取2019年1月—2021年12月福建医科大学附属福州市第一医院收治的80例卵巢癌患者,根据不同治疗药物进行分组,分别纳入单独行化疗的化疗组和行贝伐珠单抗靶向治疗的靶向组,每组40例。测评2组治疗前后肿瘤标志物蛋白芯片中糖链抗原125(glycoantigens in protein chips-125,CA-125)、人附睾蛋白4(Human epididymal protein 4,HE4)水平及血管内皮生长因子(vascular endothelial growth factor,VEGF)水平,治疗后客观缓解率、疾病控制率、免疫指标、癌症患者生命质量测定量表(quality of life scale for cancer patients,FACT-G)和抑郁自评量表(self-rating depression scale,SDS)、焦虑自评量表(self-rating anxiety scale,SAS)评分。结果治疗后,靶向组治疗客观缓解率为65.00%,疾病控制率为87.50%,高于化疗组的42.50%、70.00%(P<0.05);靶向组CA-125、HE4、VEGF指标低于化疗组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于化疗组,FACT-G评分高于化疗组,而SDS、SAS评分低于化疗组,差异有统计学意义(P<0.05)。结论贝伐珠单抗靶向治疗卵巢癌患者可抑制肿瘤新生血管形成和生长,增强治疗效果,改善患者的心理情绪和生活质量。
